Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaffer Ajani

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Annals of Surgery|June 16, 2021
Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional AnalysisCasey J Allen, David T Pointer, Alisa N Blumenthaler, et al.
Cancer Research|April 17, 2008
Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinomaChia-Jui Yen, Julie G Izzo, Dung-Fang Lee, et al.
Oncotarget|August 7, 2019
Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinomaOmkara Lakshmi Veeranki, Zhimin Tong, Rashmi Dokey, et al.
Disease Models & Mechanisms|November 17, 2019
A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveriesOmkara Lakshmi Veeranki, Zhimin Tong, Alicia Mejia, et al.
JCO Precision Oncology|September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional IndicationsEcaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
Oncotarget|April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unitDenis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
The Oncologist|March 20, 2023
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study PlatformAndrew H Ko, Kyu-Pyo Kim, Jens T Siveke, et al.
Cancer Medicine|May 8, 2024
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trialKen Kato, Yuichiro Doki, Ian Chau, et al.
The American Journal of Gastroenterology|July 6, 2004
Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resectionBanke Agarwal, Stephen Swisher, Jaffer Ajani, et al.
American Journal of Clinical Oncology|November 22, 2022
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529Jordan R Kharofa, Greg Yothers, Lisa A Kachnic, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Annals of Surgery|June 16, 2021
Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional AnalysisCasey J Allen, David T Pointer, Alisa N Blumenthaler, et al.
Cancer Research|April 17, 2008
Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinomaChia-Jui Yen, Julie G Izzo, Dung-Fang Lee, et al.
Oncotarget|August 7, 2019
Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinomaOmkara Lakshmi Veeranki, Zhimin Tong, Rashmi Dokey, et al.
Disease Models & Mechanisms|November 17, 2019
A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveriesOmkara Lakshmi Veeranki, Zhimin Tong, Alicia Mejia, et al.
JCO Precision Oncology|September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional IndicationsEcaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
Oncotarget|April 19, 2014
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unitDenis L Fontes Jardim, Debora de Melo Gagliato, Gerald S Falchook, et al.
The Oncologist|March 20, 2023
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study PlatformAndrew H Ko, Kyu-Pyo Kim, Jens T Siveke, et al.
Cancer Medicine|May 8, 2024
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trialKen Kato, Yuichiro Doki, Ian Chau, et al.
The American Journal of Gastroenterology|July 6, 2004
Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resectionBanke Agarwal, Stephen Swisher, Jaffer Ajani, et al.
American Journal of Clinical Oncology|November 22, 2022
Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529Jordan R Kharofa, Greg Yothers, Lisa A Kachnic, et al.
Pageof 11